Incyte inks $750M deal for immune and neuro biotech Escient
Incyte said it will pay $750 million to buy San Diego biotech Escient Pharmaceuticals and its pipeline of early-stage drug candidates.
The deal gives the Delaware-based drugmaker access to once-daily oral small molecules and the potential to market new medicines starting in 2029, Incyte CEO Hervé Hoppenot said in a statement Tuesday morning. Incyte already has eight approved products, including multi-indicated Jakafi, blood cancer medicine Monjuvi and eczema cream Opzelura, among others.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.